Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UCLA study uses genetic profiling to distinguish types of leprosy

12.09.2003


New approach may provide new way to diagnose, classify and treat diseases



UCLA researchers found a distinction in the gene expression of leprosy that accurately classified two different clinical forms of the disease. This is one of the first studies of its kind where genetic profiling distinguished between disease types, possibly leading to new ways to diagnose and treat all types of diseases.

The new UCLA study, published Sept. 12 in the journal Science, also identified genes belonging to a specific family of cells in the immune system that may provide potent anti-inflammatory or immune suppressant properties. These findings offer more insight into the development of leprosy, as well as new approaches to treat diseases in which the immune system causes tissue damage.


"This study is an important milestone in the new science of using genetic profiling to uncover genes linked to responses that lead to disease progression," said principal investigator Dr. Robert L. Modlin, professor of dermatology and microbiology, immunology and molecular genetics and chief, division of dermatology, David Geffen School of Medicine at UCLA. "The study also provides unanticipated insights into pathogens and targets for therapy."

According to Modlin, the future application of genetic profiling is especially interesting for infectious diseases such as leprosy or even a bioterrorist threat like anthrax.

"With genetic technology, we may be able to quickly distinguish between a common cold and early-stage anthrax, leading to earlier diagnosis and quicker treatment," he noted.

UCLA researchers biopsied 11 leprosy patients’ skin lesions, which is one of the first symptoms of the disease. Using sophisticated genetic technology and statistical methods, researchers compared expression patterns for the 12,000 genes found in the skin lesions. Researchers found that gene expressions differed for the two types of leprosy -- tuberculoid leprosy and lepromatous leprosy.

"If we can predict the clinical course of disease, we can intervene earlier," said Modlin. "This is very important for lepromatous leprosy, a more severe form of the disease that can lead to major nerve damage and disfigurement."

Researchers also found that the major difference between the gene expressions of the two types of leprosy occurred in a specific family of cells in the immune system called LIR or leukocyte immunoglobin-like receptors. Researchers found that a particular cell called LIR-7 was expressed five times more in the lepromatous lesions than in the tuberculoid lesions.

Further tests and genetic comparisons between the two lesion groups found that LIR-7 activation may actually suppress the immune system’s defenses. This may partly explain why some patients suffer from the more severe form of leprosy because these patients’ immune systems may be more compromised.

Researchers then used a tuberculosis bacteria sample to test whether LIR-7 activation would suppress the ability of the immune system to directly combat microbial pathogens. Researchers found that LIR-7 blocked the antimicrobial activity of another cell-surface receptor, called TLR or toll-like receptor. LIR-7 reduced TLR’s immune response activity from 60 percent to 20 percent.

"The immune suppression ability of LIR-7 offers us more insight into the development of infectious diseases like leprosy and also may offer future therapies for autoimmune diseases such as psoriasis or rheumatoid arthritis, where the goal is to turn off or suppress the immune system’s response," said Modlin.

According to Modlin, the next stage of the genetic research will look at leprosy’s various complications, including tissue damage and nerve damage, and try to identify which patients are susceptible to these complications.

Leprosy, one of the world’s oldest known diseases, is a chronic infectious disease. In 2003, more than 630,000 new cases of leprosy affected people worldwide, according to the World Health Organization. Leprosy continues to be an ongoing issue in developing countries.

Leprosy is caused by the bacterium "Mycobacterium leprae," and affects the skin, peripheral nerves, upper respiratory tract and eyes, and can lead to severe disfigurement of the hands, face and feet. It is uncertain how leprosy is spread, and current treatment includes a multi-drug regimen.



The study was funded by the National Institutes of Health and the World Health Organization.

Other researchers include Joshua R. Bieharski, Department of Microbiology, Immunology, and Molecular Genetics and Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles; Huiying Li, Thomas G. Graeber and David Eisenberg, Departments of Chemistry and Biochemistry and Biological Chemistry, Howard Hughes Medical Institute, UCLA -- Department of Energy Institute of Genomics and Proteomics, UCLA, Los Angeles; Christoph Meinken, Martin Rollinghoff and Steffen Stenger, Institut fur Klinische Mikrobiologie, Immunologie, und Hygiene, Universitat Erlangen, Erlangen, Germany; Maria-Teresa Ochoa, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles; Masahiro Yamamura, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan; Anne Burdick, Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, Fla.; Euzenir N. Sarno, Leprosy Laboratory Institute Oswaldo Cruz, Rio de Janeiro, Brazil; Manfred Wagner and Thomas H. Rea, Medizinische Kllnik 3, Kllnikum Nurnberg, Nurnberg, Germany; Marco Colonna, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Mo.; Barry R. Bloom, Office of the Dean, Harvard School of Public Health, Boston, Mass.

Rachel Champeau | EurekAlert!
Further information:
http://www.ucla.edu/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>